Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis

Breast Cancer Research

Volumn 13, Issue 2, 2011, Pages

  Blixt, Ola ^a   Bueti, Deanna ^b   Burford, Brian ^b,c   Allen, Diane ^b   Julien, Sylvain ^b   Hollingsworth, Michael ^d   Gammerman, Alex ^c   Fentiman, Ian ^b   Taylor Papadimitriou, Joyce ^b   Burchell, Joy M ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; MUCIN 1; EPITOPE; GLYCOPEPTIDE; MUC1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLYCOSYLATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS; BLOOD; BREAST TUMOR; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

AGED; AUTOANTIBODIES; BREAST NEOPLASMS; COHORT STUDIES; EPITOPES; FEMALE; GLYCOPEPTIDES; HUMANS; MIDDLE AGED; MUCIN-1; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860390208     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2841     Document Type: Article

References (31)

1. Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, Maudelonde T, Mangé A, Solassol J. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009, 15:4733-4741. 10.1158/1078-0432.CCR-08-3307, 19584157.
2. Hermsen BB, Verheijen RH, Menko FH, Gille JJ, van K, Blankenstein MA, Meijer S, van Diest PJ, Kenemans P, von Mensdorff-Pouilly S. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Eur J Cancer 2007, 43:1556-1563. 10.1016/j.ejca.2007.04.007, 17532207.
3. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007, 18:868-873. 10.1093/annonc/mdm007, 17347129.
4. Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 2009, 8:1197-1203. 3035104, 19556858.
5. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res 2004, 24:3221-3224.
6. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003, 21:37-38. 10.1038/nbt0103-37, 12511908.
7. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995, 1:701-702. 10.1038/nm0795-701, 7585154.
8. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006, 1:513-519. 10.1097/01243894-200607000-00003, 17409910.
9. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003, 21:57-63. 10.1038/nbt774, 12496764.
10. Desmetz C, Maudelonde T, Mangé A, Solassol J. Identifying autoantibody signatures in cancer: a promising challenge. Expert Rev Proteomics 2009, 6:377-386. 10.1586/epr.09.56, 19681673.
11. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000, 18:574-583.
12. Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR, Finn OJ, Cramer DW. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010, 19:1595-1601. 10.1158/1055-9965.EPI-10-0068, 20501761.
13. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010, 70:1306-1313. 10.1158/0008-5472.CAN-09-2893, 20124478.
14. Türeci O, Usener D, Schneider S, Sahin U. Identification of tumor-associated autoantigens with SEREX. Methods Mol Med 2005, 109:137-154.
15. Burchell J, Taylor-Papadimitriou J. O-glycosylation. Encyclopaedia of Molecular Biology 1999, 1047-1051. Chichester, West Sussex, UK: John Wiley and Sons, Inc, Creighton T.
16. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001, 6:355-364. 10.1023/A:1011331809881, 11547903.
17. Tarp MA, Sørensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, Clausen H. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007, 17:197-209. 10.1093/glycob/cwl061, 17050588.
18. Sørensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006, 16:96-107.
19. Blixt O, Cló E, Nudelman A, Sørensen K, Clausen T, Wandall H, Livingston P, Clausen H, Knud J. A high-throughput O-glycopeptide discovery platform for seromic profiling. J Prot Res 2010, 9:5250-5261.
20. Blixt O, Razi N. Chemoenzymatic synthesis of glycan libraries. Methods Enzymol 2006, 415:137-153. 10.1016/S0076-6879(06)15009-0, 17116472.
21. Bäckström M, Link T, Olson FJ, Karlsson H, Graham R, Picco G, Burchell J, Taylor-Papadimitriou J, Noll T, Hansson GC. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem J 2003, 376:677-686. 1223800, 12950230.
22. Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, Moore JW, Fentiman IS, Chaudary M, Hayward JL, et al. The relationship between blood prolactin levels and risk of breast cancer in premenopausal women. Eur J Cancer Clin Oncol 1987, 23:1541-1548. 10.1016/0277-5379(87)90098-8, 3678318.
23. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1999, 1473:67-95.
24. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000, 86:702-712. 10.1002/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1, 10797294.
25. Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007, 13:4170-4177. 10.1158/1078-0432.CCR-06-2949, 17634545.
26. Storr SJ, Royle L, Chapman CJ, Hamid UM, Robertson JF, Murray A, Dwek RA, Rudd PM. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology 2008, 18:456-462. 10.1093/glycob/cwn022, 18332077.
27. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006, 7:599-604. 10.1038/sj.embor.7400705, 1479595, 16741504.
28. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H. Core3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci USA 2005, 102:4572-4577. 10.1073/pnas.0407983102, 555466, 15755813.
29. Weksler ME, Goodhardt M. Do age-associated changes in 'physiologic' autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease?. Exp Gerontol 2002, 37:971-979. 10.1016/S0531-5565(02)00091-8, 12213547.
30. Campbell BJ, Yu LG, Rhodes JM. Altered glycosylation in inflammatory bowel disease: a possible role in cancer development. Glycoconj J 2001, 18:851-858. 10.1023/A:1022240107040, 12820718.
31. Ohyabu N, Hinou H, Matsushita T, Izumi R, Shimizu H, Kawamoto K, Numata Y, Togame H, Takemoto H, Kondo H, Nishimura S. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. J Am Chem Soc 2009, 131:17102-17109. 10.1021/ja903361f, 19899793.